Apr 19
|
MasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investors
|
Apr 19
|
12 Most Shorted Stocks in 2024
|
Apr 5
|
ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors
|
Apr 3
|
Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
|
Mar 26
|
Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”
|
Mar 8
|
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q4 2023 Earnings Call Transcript
|
Mar 8
|
Q4 2023 Phathom Pharmaceuticals Inc Earnings Call
|
Mar 7
|
Phathom Pharmaceuticals Inc (PHAT) Reports Q4 and Full Year 2023 Financials, Eyes Growth with ...
|
Mar 7
|
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
|
Feb 13
|
Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients
|
Dec 6
|
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD
|
Nov 28
|
Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn
|
Nov 1
|
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults
|
Aug 10
|
Phathom Pharmaceuticals Reports Second Quarter 2023 Results
|
May 26
|
Phathom Pharmaceuticals, Inc. (PHAT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
|
May 25
|
Should You Buy Phathom Pharmaceuticals, Inc. (PHAT) After Golden Cross?
|
May 23
|
Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock
|
May 23
|
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock
|
May 23
|
Phathom Pharmaceuticals Resubmits Erosive GERD New Drug Application to FDA
|